Literature DB >> 31103702

Wogonin pre-treatment attenuates cisplatin-induced nephrotoxicity in rats: Impact on PPAR-γ, inflammation, apoptosis and Wnt/β-catenin pathway.

Alaa M Badawy1, Reem N El-Naga2, Amany M Gad1, Mariane G Tadros3, Hala M Fawzy1.   

Abstract

Cisplatin, a platinum chemotherapeutic agent, is used in a diversity of malignancies; nevertheless, the excessive nephrotoxicity following cisplatin treatment is the dose-limiting devastating reaction. This study was designed to explore the possible nephroprotective impact of wogonin, a forceful anti-oxidant, anti-inflammatory, and anti-tumor agent, in a rat model of cisplatin-induced renal injury. The potential nephroprotective mechanisms were additionally investigated. Wogonin was given at a dose of 40 mg/kg. Acute nephrotoxicity was indicated by a significant rise in BUN, and serum creatinine levels in cisplatin-injected rats. Also, cisplatin enhanced the lipid peroxidation, diminished GSH, catalase, and PPAR-γ levels. Additionally, cisplatin-injected rats showed a significant rise in tissue levels of IL-1β, TNF-α, NF-kB, and caspase-3 enzymatic activity. Notably, the pre-treatment with wogonin ameliorated the nephrotoxicity indices, oxidative stress, inflammation, and apoptosis induced by cisplatin. Also, wogonin up-regulated PPAR-γ expression. The involvement of Wnt/β-catenin pathway was debatable; however, our findings showed that it was significantly induced by cisplatin. Wogonin pre-treatment markedly attenuated Wnt/β-catenin pathway. Collectively, these findings imply that wogonin is a promising nephroprotective agent that improves the therapeutic index of cisplatin via reducing oxidative stress, inflammation as well as inducing PPAR-γ. Also, Wnt/β-catenin pathway is partially involved in the pathogenesis of cisplatin nephrotoxicity.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cisplatin; Nephrotoxicity; PPAR-γ; Wnt/β-catenin pathway; Wogonin

Mesh:

Substances:

Year:  2019        PMID: 31103702     DOI: 10.1016/j.cbi.2019.05.029

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  7 in total

Review 1.  Therapeutic potential of PPARγ natural agonists in liver diseases.

Authors:  Liwei Wu; Chuanyong Guo; Jianye Wu
Journal:  J Cell Mol Med       Date:  2020-02-07       Impact factor: 5.310

2.  Analysis of the mechanism of Shufeng Jiedu capsule prevention and treatment for COVID-19 by network pharmacology tools.

Authors:  Haijun Xiong; Zhaowei Dong; Guanhua Lou; Qingxia Gan; Jin Wang; Qinwan Huang
Journal:  Eur J Integr Med       Date:  2020-10-30       Impact factor: 1.314

3.  Wogonin reduces cardiomyocyte apoptosis from mitochondrial release of cytochrome c to improve doxorubicin-induced cardiotoxicity.

Authors:  Yunjie Wei; Junhao Zhao; Jian Xiong; Jingjing Chai; Xi Yang; Junfeng Wang; Jiajuan Chen; Jing Wang
Journal:  Exp Ther Med       Date:  2022-01-07       Impact factor: 2.447

Review 4.  Natural products: potential treatments for cisplatin-induced nephrotoxicity.

Authors:  Chun-Yan Fang; Da-Yong Lou; Li-Qin Zhou; Jin-Cheng Wang; Bo Yang; Qiao-Jun He; Jia-Jia Wang; Qin-Jie Weng
Journal:  Acta Pharmacol Sin       Date:  2021-03-09       Impact factor: 7.169

5.  TRPA1 promotes cisplatin-induced nephrotoxicity through inflammation mediated by the MAPK/NF-κB signaling pathway.

Authors:  Jinyan Yuan; Xiao Liang; Wei Zhou; Jing Feng; Zhenyang Wang; Shaoxian Shen; Xin Guan; Liangbin Zhao; Fei Deng
Journal:  Ann Transl Med       Date:  2021-10

Review 6.  MicroRNAs Involved in Intrinsic Apoptotic Pathway during Cisplatin-Induced Nephrotoxicity: Potential Use of Natural Products against DDP-Induced Apoptosis.

Authors:  Pía Loren; Yuliannis Lugones; Nicolás Saavedra; Kathleen Saavedra; Isis Páez; Nelia Rodriguez; Patricia Moriel; Luis A Salazar
Journal:  Biomolecules       Date:  2022-08-31

7.  Effects of cisplatin on the proliferation, invasion and apoptosis of breast cancer cells following β‑catenin silencing.

Authors:  Xidan Zhu; Jia Feng; Wenguang Fu; Xiaojia Shu; Xue Wan; Jinbo Liu
Journal:  Int J Mol Med       Date:  2020-03-16       Impact factor: 4.101

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.